{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T04:19:41Z","timestamp":1743913181597,"version":"3.40.3"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072277"],"award-info":[{"award-number":["82072277"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["M21021"],"award-info":[{"award-number":["M21021"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.vaccine.2025.126722","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T03:54:03Z","timestamp":1736826843000},"page":"126722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection"],"prefix":"10.1016","volume":"48","author":[{"given":"Yuqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Coronavirus Disease (COVID-19) Situation Reports","key":"10.1016\/j.vaccine.2025.126722_bb0005"},{"key":"10.1016\/j.vaccine.2025.126722_bb0010","first-page":"e119","article-title":"Antibody efficacy of inactivated vaccine boosters (CoronaVac) against omicron variant from a 15-month follow-up study","volume":"85","author":"Yin","year":"2022","journal-title":"J Inf Secur"},{"issue":"21","key":"10.1016\/j.vaccine.2025.126722_bb0015","doi-asserted-by":"crossref","first-page":"792","DOI":"10.15585\/mmwr.mm7021e3","article-title":"CDC COVID-19 vaccine breakthrough case investigations team. COVID-19 vaccine breakthrough infections reported to CDC - United States, January 1-April 30, 2021","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.126722_bb0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/14760584.2023.2174529","article-title":"Understanding the mechanisms for COVID-19 vaccine's protection against infection and severe disease","volume":"22","author":"Yang","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126722_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.126722_bb0030","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2025.126722_bb0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(22)00732-0","article-title":"Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study","volume":"23","author":"Tsang","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126722_bb0040","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.vaccine.2024.01.080","article-title":"Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection","volume":"42","year":"2024","journal-title":"Vaccine"},{"author":"Omicron and cold-like symptoms rapidly taking over in London","key":"10.1016\/j.vaccine.2025.126722_bb0045"},{"key":"10.1016\/j.vaccine.2025.126722_bb0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(22)00017-4","article-title":"Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study","volume":"399","author":"Wolter","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126722_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101455","article-title":"Severe hospital events following symptomatic infection with Sars-CoV-2 omicron and Delta variants in France, December 2021\u2013January 2022: a retrospective, population-based, matched cohort study","volume":"48","author":"Auvigne","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.vaccine.2025.126722_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe4782","article-title":"Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells","volume":"6","author":"Kusnadi","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2025.126722_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-immunol-101721-061120","article-title":"T cell responses to SARS-CoV-2","volume":"41","author":"Sette","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.126722_bb0070","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.immuni.2021.05.010","article-title":"Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease","volume":"54","author":"Bergamaschi","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.126722_bb0075","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41392-021-00686-1","article-title":"SARS-CoV-2-specific immune response in COVID-19 convalescent individuals","volume":"6","author":"Pan","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2025.126722_bb0080","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/v13071364","article-title":"Neutralizing antibodies in COVID-19 patients and vaccine recipients after two doses of BNT162b2","volume":"13","author":"Favresse","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.126722_bb0085","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S1473-3099(21)00420-5","article-title":"Heterologous prime\u2013boost vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"21","author":"Tenbusch","year":"2021","journal-title":"Lancet Infect Dis"},{"year":"2019","series-title":"Novel coronavirus information database","author":"China\/ Real-time Surveillance Report","key":"10.1016\/j.vaccine.2025.126722_bb0090"},{"key":"10.1016\/j.vaccine.2025.126722_bb0095","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.126722_bb0100","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126722_bb0105","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.126722_bb0110","article-title":"Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies","volume":"2","author":"Dufloo","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2025.126722_bb0115","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126722_bb0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2021.12.040","article-title":"Complement activation induces excessive T cell cytotoxicity in severe COVID-19","volume":"185","author":"Georg","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126722_bb0125","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jiph.2022.12.016","article-title":"Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar","volume":"16","author":"Tayar","year":"2023","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.vaccine.2025.126722_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009928","article-title":"Induction of trained immunity by influenza vaccination - impact on COVID-19","volume":"17","author":"Debisarun","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2025.126722_bb0135","article-title":"Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil","author":"Fink","year":"2020","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.vaccine.2025.126722_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.802858","article-title":"Characterization of SARS-CoV-2-specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126722_bb0145","doi-asserted-by":"crossref","first-page":"e792","DOI":"10.1093\/cid\/ciab823","article-title":"Safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in a subgroup of healthy adults in Chile","volume":"75","author":"Bueno","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126722_bb0150","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41564-022-01161-5","article-title":"Inactivated whole-virion vaccine BBV152\/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern","volume":"7","author":"Vikkurthi","year":"2022","journal-title":"Nat Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T18:01:19Z","timestamp":1743876079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25000192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"alternative-id":["S0264410X25000192"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126722","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126722"}}